Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.71 |
| ▸ | HTR1B | P28222 | 9/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.65 |
| ▸ | HTR1A | P08908 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629115 | 0.90 | HTR1D (0.66) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL953962 | 0.90 | HTR1D (0.70) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL22953216 | 0.83 | HTR1D (0.78) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL953076 | 0.83 | HTR1D (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL953214 | 0.82 | HTR1D (0.62) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL7969470 | 0.81 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL953638 | 0.80 | HTR1D (0.76) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL26078561 | 0.80 | HTR1D (0.76) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL7982884 | 0.80 | HTR1D (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL4629825 | 0.80 | HTR1D (0.86) | HTR1DHTR1BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES INC | 2017-08-03 | — | — | US | disclosed |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | Galderma Laboratories, L.P. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9186358-B2 | Combination therapy for treating or preventing an inflammatory skin disorder | Galderma Laboratories, L.P. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | Galderma Laboratories, L.P. (US) | 2015-07-23 | — | — | US | disclosed |
| US-9072739-B2 | Method for treating psoriasis | Galderma Laboratories, L.P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8993571-B2 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | Galderma Laboratories, L.P. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8859551-B2 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | GALDERMA LABORATORIES INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8557817-B2 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | GALDERMA LABORATORIES INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130243837-A1 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging | GALDERMA LABORATORIES INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130184283-A1 | METHOD FOR TREATING PSORIASIS | Galderma Laboratories, L.P. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120277241-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8231885-B2 | Compounds, formulations, and methods for ameliorating telangiectasis | GALDERMA LABORATORIES INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110286945-A1 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging | GALDERMA LABORATORIES INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110118267-A1 | Method and Kit for Treating or Preventing Psoriasis | Galderma Laboratories, L.P. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7838563-B2 | Compounds, formulations, and methods for ameliorating telangiectasias | GALDERMA LABORATORIES INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100227867-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100130502-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100021402-A1 | Compounds, Formulations, and Methods for Ameliorating Telangiectasis | GALDERMA LABORATORIES INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090060852-A1 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging | GALDERMA LABORATORIES INC. | 2009-03-05 | — | — | US | disclosed |
| US-7439241-B2 | Compounds, formulations, and methods for treating or preventing rosacea | GALDERMA LABORATORIES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021402-A1 | Compounds, Formulations, and Methods for Ameliorating Telangiectasis | TEK, ADRB1, TBXA2R | HTR1D 398/4885HTR1B 432/4885ADRA2A 10/4885 |
| US-20120277241-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HTR1D 347/4885HTR1B 300/4885ADRA2A 120/4885 |
| US-20100130502-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HTR1D 347/4885HTR1B 300/4885ADRA2A 120/4885 |
| US-20100227867-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HTR1D 347/4885HTR1B 300/4885ADRA2A 120/4885 |
| US-20090060852-A1 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging | ADRA2A, ADRA2C, ADRA2B | HTR1D 144/4885HTR1B 69/4885ADRA2A 1/4885 |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HRH4, HRH1, HRH3 | HTR1D 347/4885HTR1B 300/4885ADRA2A 120/4885 |
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HTR1D 347/4885HTR1B 300/4885ADRA2A 120/4885 |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HTR1D 347/4885HTR1B 300/4885ADRA2A 120/4885 |
| US-20110118267-A1 | Method and Kit for Treating or Preventing Psoriasis | ADRB2, ADRA2A, ADRA2C | HTR1D 903/4885HTR1B 464/4885ADRA2A 2/4885 |
| US-20130184283-A1 | METHOD FOR TREATING PSORIASIS | ADRB2, ADRA2A, ADRA2C | HTR1D 998/4885HTR1B 572/4885ADRA2A 2/4885 |
| US-20110286945-A1 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging | ADRA2A, ADRA2C, ADRA2B | HTR1D 144/4885HTR1B 69/4885ADRA2A 1/4885 |
| US-20130243837-A1 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging | ADRA2A, ADRA2C, ADRA2B | HTR1D 144/4885HTR1B 69/4885ADRA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.